Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
Authors
Bruce A. Perkins (ORCID: https://orcid.org/0000-0002-5885-0046)
Tosin Osuntokun
Josephine Tse
Daan J. Touw (ORCID: https://orcid.org/0000-0002-1429-4789)
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
Bruce A. Perkins, Tosin Osuntokun, Josephine Tse, Daan J. Touw et al.
Journal
Hypertension
Topics
Diabetes Treatment and Management
article
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
Bruce A. Perkins, Tosin Osuntokun, Josephine Tse, Daan J. Touw, Massimo Nardone, Brian Y.H. Lam, Dylan Burger, David Z.I. Cherney, Leif E. Lovblom, Hiddo J.L. Heerspink, Ryan Lam, Hongyan Liu, Vikas S. Sridhar, Tomoyuki Tobushi, Yangqing Deng, Yuliya Lytvyn, Luxcia Kugathasan, Julie A. Lovshin, Jasper Stevens, John S. Floras
article en
Abstract
No abstract available for this paper.
Publication Tag
HypertensionVol. 83(2)
Institutions
Mount Sinai Hospital (CA), Sunnybrook Health Science Centre (CA), University Health Network (CA), University Medical Center Groningen (NL), University of British Columbia (CA), University of Toronto (CA), Lunenfeld-Tanenbaum Research Institute (CA), Ottawa Hospital (CA), Institute of Health Services and Policy Research (CA)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial — Bruce A. Perkins, Tosin Osuntokun, et al. · Hypertension (2025) | TGRS Research Map | TGRS